Patient Characteristics and PET/CT Results
| Patient no. | Age (y) | Initial PSA (ng/mL) | Gleason score | pTNM | Primary therapy | Date of primary therapy | Salvage therapy | Date of salvage therapy | Prior imaging within past 3 mo | 18F-fluciclovine | 68Ga-PSMA-11 | Management strategy after 68Ga-PSMA-11 |
| 1 | 65 | 7.8 | 4 + 3 = 7 | cT2c | XRT + brachy + ADT | 2014 | CT + Na-F | 0 | N1 M1aM1b | ADT | ||
| 2 | 76 | 7.17 | 4 + 3 = 7 | pT3b N0 Mx | RP | 2009 | SRT + ADT | 2012 | CT + mpMRI + choline | 0 | N1 M1bM1c | Proton therapy on bone met |
| 3 | 63 | 20.6 | 4 + 4 = 8 | NA | XRT + brachy + ADT | 2015 | CT+ Na-F | T+ | T+ M1a | ADT | ||
| 4 | 72 | NA | 3 + 4 = 7 | pT2c N0 Mx | RP | 2002 | SRT + ADT | 2016 | mpMRI | 0 | 0 | Active surveillance |
| 5 | 78 | 5.1 | 4 + 5 = 9 | pT2b | RP | 2009 | SRT | 2012 | mpMRI + Na-F | 0 | N1 | Active surveillance |
| 6 | 67 | 4.5 | 4 + 5 = 9 | pT3b N0 | RP + adj XRT + ADT | 2015 | Choline | 0 | 0 | Active surveillance | ||
| 7 | 72 | NA | 4 + 3 = 7 | pT3b | RP | 2017 | mpMRI | N1 | N1 | LN dissection | ||
| 8 | 71 | 7.9 | 3 + 4 = 7 | pT2c N0 Mx | RP | 2014 | CT + mpMRI | 0 | 0 | SRT | ||
| 9 | 74 | 5 | NA | NA | RP + adj XRT | 2008 | ADT | 2013–2017 | CT+ Na-F | 0 | N1 M1a | ADT |
| 10 | 70 | 6 | 5 + 4 = 9 | pT2 N0 Mx | RP | 2011 | SRT | 2015 | CT+ Na-F | 0 | N1 | Ablative RT on single LN met |
XRT = external-beam radiation therapy; brachy = brachytherapy; Na-F = 18F-fluoride PET/CT; RP = radical prostatectomy; SRT = salvage radiation therapy; mpMRI = multiparametric MRI; choline = 11C-choline PET/CT; met = metastasis; NA = not applicable; adj = adjunctive; RT = radiotherapy.